Pfizer Fortune 500 TURBO Report
Pfizer Fortune 500 TURBO Report
Last updated: H1 2020
235 East 42nd Street
New York, NY 10017
Industry: Drug Manufacturers - Major
Full Time Employees: 92,400
The Pfizer databahn TURBO Report was researched and developed with the IT sales executive and the IT marketer in mind. Our goal is simple; eliminate the costly research time and help you identify new sales revenue opportunities.
Top 10 reasons to buy the Pfizer databahn TURBO company profile report:
- Create a better and more informed RFP Response proposal
- Brief your C-level executives before a sales call
- Eliminate the time it takes to build a strategic account plan
- Develop more effective account based marketing (ABM) programs
- Discover sales opportunities you're not aware of
- Understand the competitive landscape in the account
- Ramp up new sales reps faster in new accounts
- Need accurate contact information & org charts
- Insights into IT projects & initiatives
- Expand footprint in existing large enterprise accounts
Some of the insights & detailed information you can expect to see in the Pfizer databahn TURBO Report:
- Comprehensive Business Description
- Latest Earnings Call Highlights from the CEO
- Accurate Contacts for the Executive Leadership Team and Board of Directors
- Detailed Org Charts on corporate structure, board of directors, and the executive leadership team
- Hand curated content from selected articles, interviews, case studies, and success stories (representing dozens of hours of research)
- Technology Executive Insights to existing IT & telecom systems, projects, initiatives, and internal code names for applications, systems, and IT business units
- Insights gleaned from technology related job descriptions
- Important excerpts and highlights from the Annual Report (10-K)
Available for download now!
PFIZER EXECUTIVE LEADERSHIP
|Albert Bourla||Chief Executive Officer||Pfizeremail@example.com|
|Angela Hwang||Group President, Pfizer Biopharmaceuticals Group||Pfizerfirstname.lastname@example.org|
|Dawn Rogers||Executive Vice President, Chief Human Resources Officer||Pfizeremail@example.com|
|Doug Lankler||Executive Vice President, General Counsel||Pfizerfirstname.lastname@example.org|
|Frank D'Amelio||Chief Financial Officer and Executive Vice President, Global Supply and Business Operations||Pfizeremail@example.com|
|Freda C. Lewis-Hall||Chief Patient Officer and Executive Vice President||Pfizerfirstname.lastname@example.org|
|John Young||Group President, Chief Business Officer||Pfizeremail@example.com|
|Lidia Fonseca||Executive Vice President, Chief Digital and Technology Officer||Pfizerfirstname.lastname@example.org|
|Michael Goettler||Group President, Pfizer Upjohn||Pfizeremail@example.com|
|Mikael Dolsten||Chief Scientific Officer and President, Worldwide Research, Development and Medical||Pfizerfirstname.lastname@example.org|
|Rady Johnson||Executive Vice President, Chief Compliance, Quality & Risk Officer||Pfizeremail@example.com|
|Rod MacKenzie||Executive Vice President, Chief Development Officer||Pfizerfirstname.lastname@example.org|
|Sally Susman||Executive Vice President, Chief Corporate Affairs Officer||Pfizeremail@example.com|
PFIZER BOARD OF DIRECTORS
|Ian C. Read||Executive Chairman of the Board||Pfizerfirstname.lastname@example.org|
|Ronald E. Blaylock||Founder, Managing Partner of Gennx360 Capital Partners||Pfizeremail@example.com|
|Albert Bourla||Chief Executive Officer, Pfizer||Pfizerfirstname.lastname@example.org|
|Don Cornwell||Former Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporation||Pfizeremail@example.com|
|Joseph J. Echevarria||Former CEO of Deloitte LLP. Director of The Bank of New York Mellon Corporation, Unum Group, and Xerox Corporation||Pfizerfirstname.lastname@example.org|
|Scott Gottlieb||Former Commissioner of the U.S. Food and Drug Administration||Pfizeremail@example.com|
|Helen H. Hobbs||Investigator, the Howard Hughes Medical Institute||Pfizerfirstname.lastname@example.org|
|James M. Kilts||Founding Partner Centerview Capital, Former Vice Chairman The Procter & Gamble Company, Former Chairman and CEO The Gillette Company||Pfizeremail@example.com|
|Dan R. Littman||Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and an Investigator of the Howard Hughes Medical Institute||Pfizerfirstname.lastname@example.org|
|Shantanu Narayen||Chairman, President and CEO of Adobe Systems Incorporated||Pfizeremail@example.com|
|Suzanne Nora Johnson||Retired Vice Chairman, Goldman Sachs Group, Inc||Pfizerfirstname.lastname@example.org|
|James C. Smith||President, CEO and Director of Thomson Reuters Corporation||Pfizeremail@example.com|
7 KEYS TO OPEN DOORS AT PFIZER
Pfizer to announce more jobs, investment at Sanford, NC plant
- The new initiative is focused on gene therapy. Pfizer operates a gene therapy research facility at the Sanford complex.
- “The new facility will help advance Pfizer’s work in researching highly specialized, potentially one-time gene therapy treatments that use custom-made adeno-associated virus (AAV) vectors to deliver treatment effectively to patients” according to Pfizer.
Pfizer will combine its off-patent drug business with Mylan
- Pfizer, the world’s largest drugmaker, plans to divest its off-patent drug business and combine it with generic-drug maker Mylan.
- Under the agreement, which is structured as an all-stock deal, each Mylan share would be converted into one share of the new company.
- Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%, Mylan said.
Pfizer acquires Array BioPharma
- Pfizer announced in mid-June that it would buy Array (ARRY) in a deal worth a reported $10.6 billion.
FDA Approves Pfizer's Rituximab Biosimilar, Ruxience
- The FDA has approved Pfizer’s rituximab biosimilar, Ruxience (rituximab-pvvr), referencing Rituxan. The biosimilar was approved to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.
- The fact that the biosimilar was not approved for all indications of its reference, a Pfizer representative told The Center for Biosimilars® in an email, is due to the fact that “Genentech has exclusivity for rituximab in certain indications. Pfizer has agreed to the terms of a global settlement,” but “specific terms and conditions of the settlement are confidential.”
Pfizer buys stake in French gene therapy firm Vivet
- Pfizer Inc said it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company’s experimental gene therapy for a rare genetic disorder called Wilson disease.
- Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8 million in clinical, regulatory milestone payments and to exercise the option to buy the whole company.
The U.S. Food and Drug Administration approved Pfizer Inc’s oral drug, tafamidis
- The U.S. Food and Drug Administration approved Pfizer Inc’s oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy.
- Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel.
Pfizer will shut down its injectables facility in Irungattukottai, India, as well as another site in Aurangabad, India
- More than three years after snapping up Hospira, Pfizer has finally decided that some of its manufacturing facilities in India are beyond redemption.
- The U.S. pharma will shut down its long-troubled injectables facility in Irungattukottai, India, as well as another site in Aurangabad, India, both of which were folded into Pfizer through the $15 billion acquisition of Hospira in 2015.